METASTATIC SOLID TUMORS
Clinical trials for METASTATIC SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new METASTATIC SOLID TUMORS trials appear
Sign up with your email to follow new studies for METASTATIC SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…
Matched conditions: METASTATIC SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat cancers in major trial
Disease control OngoingThis study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Part…
Matched conditions: METASTATIC SOLID TUMORS
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Matched conditions: METASTATIC SOLID TUMORS
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets Hard-to-Treat cancers with MET mutations
Disease control OngoingThis early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…
Matched conditions: METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC